At Rarity Bioscience we are aiming at radically improving cancer diagnostic. We are developing a technology with the power of saving people’s lives. The technology is time efficient, high sensitive and allow optimal clinical decisions at the right time to improve patient outcome. Our assay technology is based on the groundbreaking discovery of SuperRCA (Prof. Ulf Landegren and Dr. Lei Chen) – here is the evidence.
New perspective article on Liquid Biopsy using superRCA
From Uppsala University and Karolinska Institute: This perspective article compares existing techniques and the benefits and drawbacks of various types of assays for different applications, and their utility for diagnosis and monitoring. The authors discuss molecular methods for monitoring malignancies, particularly leukemias, and compare them to the super rolling circle amplification, superRCA, technique that enables highly sensitive measurement of mutant sequences using accessible instruments.
Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
With an innovative, super sensitive technology, so-called superRCA analyzes, any remaining cancer cells can be detected after treatment of acute myeloid leukemia (AML). The method is presented in an article in Nature Communication, this is the technology on which Rarity Bioscience is based and the article describes the application in Leukemia.
Molecular tools to monitor health and disease – and lucky coincidences
New poster presented at ISMRC conference
CEO Linus Bosaeus, CTO Lei Chen and Dir. BD Alexander Kele attended the ISMRC (International Symposium on Minimal Residual Cancer) Conference in Hamburg, Germany, 2023, to present a new poster. The poster demonstrates initial data from a pilot study looking at the utility of cfDNA mutation detection in low volumes of blood plasma to monitor treatment and residual disease using the ultra-sensitive superRCA assays.
MRD poster presented at AML conference
CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen presented poster #79 during the AML Conference, to discuss the main topics, such as novel target therapies and markers for Diagnosis and Prognosis. The poster demonstrates positive results from a pilot study looking at the utility of using peripheral blood vs. bone marrow for molecular MRD using the ultra-sensitive superRCA assays.
European Society for Medical Oncology
Dr. Lei Chen presented poster #629P; Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays –winning Best Poster award 2022. The scientific committee pointed out that the data provided new and valuable perspectives for monitoring of Leukemia patients.
Cancer Research conference
Poster presentation by Lei Chen,PhD at the European Association for Cancer Research conference on Liquid Biopsy in Bergamo, Italy. The poster focused on the superRCA single tube assay workflow, the assay sensitivity and precision, followed by multiplex example from colorectal patients.
Nordic Flow Cytometry
Lei Chen, PhD attended the Nordic Flow Cytometry meeting in Oslo where he presented this poster on the topic of Ultra-sensitive monitoring of leukemia patients using SuperRCA mutation detection assays with Flow Cytometer Readout.
ELC301 translational study
On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells.
Follow us
Sitemap
Contact us
